Published in Radiology on February 01, 1990
Disappearing saccular intracranial aneurysms: do they really disappear? Interv Neuroradiol (2007) 0.86
Thrombosis and recanalization of small saccular cerebral aneurysm : two case reports and a suggestion for possible mechanism. J Korean Neurosurg Soc (2014) 0.80
Thrombogenic potential of nonionic contrast media? Radiology (1990) 0.75
Spontaneous Occluded Anterior Communicating Artery Aneurysm during Coil Embolization Treated with One Coil Insertion into Remaining Stump. J Cerebrovasc Endovasc Neurosurg (2015) 0.75
Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study. PLoS One (2016) 0.75
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 1.64
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost (1999) 1.42
Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Circulation (1993) 1.42
Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J Med Chem (1990) 1.16
Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost (2009) 1.09
Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. J Am Coll Surg (1994) 1.07
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol (1998) 0.99
Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost (2005) 0.95
Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. J Burn Care Rehabil (1997) 0.94
Antithrombin III concentrate in the acute phase of thermal injury. Burns (2000) 0.90
The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma (1992) 0.88
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb Res (2000) 0.87
Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol (2000) 0.87
The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Burns (2001) 0.86
Low molecular weight heparins. An objective overview. Drugs Aging (1992) 0.86
Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost (1996) 0.85
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost (2000) 0.84
Low molecular weight heparins: are they different? Can J Cardiol (1998) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis (1988) 0.82
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Thromb Res (1999) 0.82
In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Thromb Res (1997) 0.82
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Blood Coagul Fibrinolysis (1991) 0.82
Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification. Radiology (1992) 0.81
A new approach in monitoring recombinant hirudin during cardiopulmonary bypass. Semin Thromb Hemost (1993) 0.81
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis (1988) 0.81
Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res (1997) 0.81
Recombinant hirudin--initial observations in reconstructive microsurgery. Haemostasis (1991) 0.81
Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost (1998) 0.80
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res (1995) 0.80
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost (1982) 0.80
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost (1997) 0.80
Ethylenediaminetetraacetic acid (EDTA) in heparin. Thromb Res (1998) 0.80
Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression. Thromb Res (2000) 0.80
Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci (1989) 0.80
Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost (1985) 0.79
Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. Thromb Res (1994) 0.79
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Semin Thromb Hemost (1985) 0.79
Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic status. Semin Thromb Hemost (1984) 0.79
Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. J Burn Care Rehabil (2000) 0.79
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods. Semin Thromb Hemost (1983) 0.79
In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). Semin Thromb Hemost (1985) 0.79
Trauma and thermal injury: comparison of hemostatic and cytokine changes in the acute phase of injury. J Trauma (1998) 0.79
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost (1999) 0.78
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost (1999) 0.78
Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin Thromb Hemost (1985) 0.78
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Haemostasis (1991) 0.78
Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Semin Thromb Hemost (1985) 0.78
Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma. J Interferon Cytokine Res (1998) 0.78
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a review. Arch Pathol Lab Med (2000) 0.78
Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. Semin Thromb Hemost (1991) 0.77
The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res (1992) 0.77
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. Thromb Res (1991) 0.77
Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost (1996) 0.77
Effects of a heparin-binding protein on blood coagulation and platelet function. Semin Thromb Hemost (2001) 0.77
Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Ann Thorac Surg (1996) 0.77
Pharmacology of argatroban. Expert Opin Investig Drugs (1999) 0.77
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost (1999) 0.76
Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol (1995) 0.76
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Semin Thromb Hemost (1989) 0.76
Complexes of platelet factor 4 and heparin activate Toll-like receptor 4. J Thromb Haemost (2015) 0.76
Low molecular weight heparins: a developmental perspective. Expert Opin Investig Drugs (1997) 0.76
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res (1996) 0.76
Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty. Semin Thromb Hemost (1991) 0.76
Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol (1990) 0.76
Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost (1985) 0.76
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model. Thromb Res (1995) 0.76
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion (2001) 0.76
Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res (1986) 0.75
Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Clin Appl Thromb Hemost (2001) 0.75
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Hemost (1999) 0.75
Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinolysis (1999) 0.75
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGF. Mediators Inflamm (1993) 0.75
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. Clin Appl Thromb Hemost (1999) 0.75
Statins induce hypothrombotic states? Clin Appl Thromb Hemost (2000) 0.75
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost (1999) 0.75
Inadequacy of current prevention strategies for heparin-induced thrombocytopenia. Clin Appl Thromb Hemost (1999) 0.75
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem (1983) 0.75
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Int Angiol (1999) 0.75
Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology . Int Angiol (2012) 0.75
Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspective. Semin Thromb Hemost (1999) 0.75
Pharmacokinetics of argatroban in primates: evidence on endogenous uptake. Int Angiol (2000) 0.75
Automated clot-based methods in coagulation testing: current and future considerations. Semin Thromb Hemost (1983) 0.75
Synthetic and recombinant antithrombin drugs. Expert Opin Investig Drugs (1998) 0.75
Emerging anticoagulant and thrombolytic drugs. Expert Opin Emerg Drugs (2001) 0.75
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overview. Clin Chem (1983) 0.75
Evaluation of "Statsep," a semiautomated device to prepare plasma samples for coagulation analysis. Semin Thromb Hemost (1983) 0.75
The pulmonary veins. Semin Roentgenol (1989) 0.75
Bleeding complications with glycoprotein IIb/IIIa inhibitors. Drugs Today (Barc) (2000) 0.75
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clin Appl Thromb Hemost (1999) 0.75
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost (1999) 0.75
Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol Oncol Clin North Am (2000) 0.75
Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost (1999) 0.75
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteases. Adv Exp Med Biol (1983) 0.75
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost (1999) 0.75
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates. Thromb Res (2000) 0.75
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. J Card Surg (2005) 0.75
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thromb Res (2001) 0.75
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am (1998) 0.75